|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XX72
|
|
gptkbp:CASNumber
|
gptkb:193275-84-2
|
|
gptkbp:contraindication
|
hypersensitivity to lonafarnib
|
|
gptkbp:developer
|
gptkb:Eiger_BioPharmaceuticals
gptkb:Merck_&_Co.
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:hasMolecularFormula
|
C27H31N5O2
|
|
gptkbp:hasSMILES
|
CC1=CC(=C(C=C1)NC(=O)C2=CC=CC=C2)C3=NC=NC(=N3)N4CCN(CC4)CCO
|
|
gptkbp:indication
|
progeroid laminopathies
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:farnesyltransferase_inhibitor
|
|
gptkbp:otherName
|
gptkb:SCH66336
gptkb:Zokinvy
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
16039398
CHEMBL1201832
DB06435
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
diarrhea
fatigue
increased liver enzymes
|
|
gptkbp:UNII
|
6Z5B6HVF6O
|
|
gptkbp:usedFor
|
treatment of Hutchinson-Gilford progeria syndrome
|
|
gptkbp:bfsParent
|
gptkb:Harvey_rat_sarcoma_viral_oncogene_homolog
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lonafarnib
|